Back to News
Market Impact: 0.42

Wedbush reiterates Palantir stock rating on strong guidance raise

PLTR
Corporate EarningsCorporate Guidance & OutlookAnalyst InsightsCompany FundamentalsArtificial IntelligenceTechnology & Innovation
Wedbush reiterates Palantir stock rating on strong guidance raise

Wedbush reiterated an Outperform rating on Palantir and lifted its price target to $230, citing a strong Q2 fiscal 2026 beat and raised full-year guidance. Palantir now expects fiscal 2026 revenue of $7.650B-$7.662B versus prior guidance of $7.182B-$7.198B and above the $7.240B Street estimate, while adjusted operating income is guided to $4.440B-$4.452B and free cash flow to $4.200B-$4.400B. U.S. commercial revenue is projected to grow 120% year over year, underscoring continued AI-driven demand.

Analysis

The market is likely to keep rewarding PLTR on the fastest path to monetization, but the bigger signal is that the business is still in the early phase of S-curve adoption rather than a mature software compounder. Revisions to revenue and FCF guidance at this scale imply operating leverage is compounding faster than consensus models, which usually forces a multiple re-rating before fundamentals fully catch up. That said, once growth expectations reset this aggressively, the stock becomes more sensitive to even small execution misses than to absolute growth slowdown. Second-order winners are the adjacent AI infrastructure names that benefit from the “boardroom budget unlock” effect: once a large enterprise signs off on Palantir spend, it typically accelerates adjacent spending on cloud, data integration, and security layers. The losers are more traditional system integrators and analytics vendors whose value proposition weakens when a platform proves it can replace labor-heavy deployment with software-led rollouts. Over the next 6-12 months, the key question is not whether PLTR can grow, but whether that growth is broad-based enough to prevent customer concentration or sales-cycle elongation from becoming the next narrative. The main contrarian risk is valuation not at the stock-price level, but at the expectations level: at this multiple, the market is already discounting sustained hypergrowth into 2027 and beyond. If U.S. commercial growth decelerates from triple digits into the 60-80% range, the stock can de-rate sharply even if fundamentals remain excellent. The setup is therefore asymmetric for holders: good quarters may only maintain the premium, while any hint of normalization can compress it quickly. Catalyst-wise, the next 1-2 quarters matter more than the next year because they will show whether this is a repeatable enterprise adoption cycle or a few large deal wins. Watch for management commentary on contract duration, net retention, and whether international and government growth can re-accelerate to diversify the story. If those improve, the multiple can still expand; if not, this becomes a momentum name with fragile support.